CADL: Aglatimagene nears BLA submission after positive phase III data, with focused launch and key catalysts ahead
Two viral immunotherapies are advancing in clinical trials, with aglatimagene showing strong phase III results in prostate cancer and a BLA submission planned for year-end. The commercial launch will focus on top accounts, with positive payer feedback and key upcoming data on biomarkers and surviva…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.